HCPCS Level II code Q5158 designates a 1 mg dose of denosumab-bnht (bomyntra/conexxence), a biosimilar denosumab product administered by subcutaneous injection. This code enables payers and providers to classify and bill for the biosimilar formulation of denosumab used in bone-modifying therapy and related indications. Nationally, biosimilar HCPCS codes matter for managing biologic utilization, supply-chain tracking, and payer coverage policies as biosimilars expand therapeutic options and influence cost dynamics.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical and administrative context, typical sites of service, and the common modifiers and billing elements associated with HCPCS Level II injectable biologics. The publication summarizes benchmarks and coverage considerations relevant to billing, documentation, and claims processing for denosumab biosimilars, highlights policy updates affecting biosimilar coding and reimbursement, and provides practical references for payer communications and claim submissions. Data not available in the input will be noted where applicable.